Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.
F&O Talk: Big break above 23,200 can open doors for 23,500 for Nifty; Sudeep Shah picks 6 stocks ahead of Diwali
Nifty could extend its recovery towards 23,500 if it decisively breaks above the 23,150–23,200 resistance zone, says SBI Securities’ Sudeep Shah. He also shares his
October 31, 2026